A Phase 3 interventional study of Cabozantinib and Nivolumab in Renal Cell Carcinoma, sponsored by Exelixis. Active, not recruiting at 159 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Exelixis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing cabozantinib in Carcinoma, Renal Cell — 11 open to participants now, 23 under way, 4 of them phase 3. cabozantinib · Carcinoma, Renal Cell.
Among the 42 studies testing cabozantinib in Carcinoma, Renal Cell, this one is the 5th largest by enrollment, is one of 6 that started in 2019, is one of 6 in phase 3, reaches primary completion later than 1 of the 22 other live ones, and was the 19th registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.
Browse Carcinoma, Renal Cell studies →11 of the 42 studies testing cabozantinib in Carcinoma, Renal Cell are open now, in 6 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
dr. Tom van der Hulle · Sites in Netherlands
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 70+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
By country, each count listing its studies:
cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cabozantinib is the treatment under test here. Read study by study →
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 27 · Phase 3 6 · Phase 4 1
First in 2010; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 855 is above the median of 43 across 1,566 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 44 across the 42 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 42 have an industry lead sponsor. The 10 most frequent:
Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
10 studies in Carcinoma, Renal Cell by Exelixis: 2 open now, 6 under way, 3 of them phase 3. Of 4 finished, 1 (25%) have results posted.
Among the 10 studies in Carcinoma, Renal Cell by Exelixis, this one is the 4th largest by enrollment, is one of 2 that started in 2019, is one of 4 in phase 3, and was the 5th registered.
Exelixis’s Carcinoma, Renal Cell studies by the year they started, since 2010.
13 of the studies testing cabozantinib in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05263050Fox Chase Cancer CenterTrial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | 2026-12 |
| NCT04413123Bradley A. McGregor, MDCabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | 2026-12-20 |
| NCT06835972Memorial Sloan Kettering Cancer CenterA Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | 2027-02 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
| NCT07187869M.D. Anderson Cancer CenterModulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study | 2027-04-07 |
Add all 13 to your calendar (.ics) → With an account.
Among the 42 studies testing cabozantinib in Carcinoma, Renal Cell, from their registry updates:
Among Exelixis’s 10 in Carcinoma, Renal Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 840 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio at approximately 180 sites.
This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. The primary objective of this study is to evaluate the effect of cabozantinib in combination with nivolumab and ipilimumab ("triplet") on the duration of progression-free survival (PFS) versus nivolumab and ipilimumab. A secondary objective is to evaluate the effect of triplet combination on the duration of overall survival (OS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other clinically significant disorders such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cabozantinib + nivolumab + ipilimumab (4 doses) followed by cabozantinib + nivolumab
Drug: Cabozantinib · Biological: Nivolumab · Biological: Ipilimumab
Cabozantinib-matched placebo + nivolumab + ipilimumab (4 doses) followed by cabozantinib-matched placebo + nivolumab
Biological: Nivolumab · Biological: Ipilimumab · Drug: Cabozantinib-matched placebo
Specified dose on specified days.
Also known as: Cabometyx, XL184
Specified dose on specified days.
Also known as: Opdivo, BMS-936558
Specified dose on specified days.
Also known as: Yervoy, BMS-734016
Specified dose on specified days.
Duration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC)
Duration of PFS was defined as the time from randomization to the earlier of either the date of radiographic progression per BIRC or the date of death due to any cause. PFS (months) = (earliest date of progression, death, censoring - date of randomization + 1)/30.4375. PFS was determined as per Response Evaluation Criteria in Solid Tumors version (RECIST) v1.1.
Time frame: Up to 32 months
Duration of Overall Survival (OS)
Duration of OS (months) = (earliest date of death or censoring - date of randomization + 1)/30.4375.
Time frame: Up to 58 months
| Milestone | Cabozantinib + Nivolumab + Ipilimumab | Placebo + Nivolumab + Ipilimumab |
|---|---|---|
| Started | 428 | 427 |
| Received at least 1 dose of study drug | 426 | 423 |
| Progression free survival (pfs) intent-to-treat (pitt) population | 276 | 274 |
| Safety analysis set | 426 | 423 |
| Intent to treat (itt) population | 428 | 427 |
| Completed | 185 | 187 |
| Not completed | 243 | 240 |
| Withdrew: Death | 223 | 211 |
| Withdrew: Withdrawal by subject | 17 | 25 |
| Withdrew: Lost to follow-up | 3 | 4 |
Duration of PFS was defined as the time from randomization to the earlier of either the date of radiographic progression per BIRC or the date of death due to any cause. PFS (months) = (earliest date of progression, death, censoring - date of randomization + 1)/30.4375. PFS was determined as per Response Evaluation Criteria in Solid Tumors version (RECIST) v1.1.
| months | Cabozantinib + Nivolumab + Ipilimumab | Placebo + Nivolumab + Ipilimumab |
|---|---|---|
| Duration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC) | NA (14.00 to NA) | 11.30 (7.69 to 18.17) |
Duration of OS (months) = (earliest date of death or censoring - date of randomization + 1)/30.4375.
| months | Cabozantinib + Nivolumab + Ipilimumab | Placebo + Nivolumab + Ipilimumab |
|---|---|---|
| Duration of Overall Survival (OS) | 41.86 (34.79 to 47.87) | 41.99 (34.92 to 53.13) |
Collected over Day 1 up to 58 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cabozantinib + Nivolumab + Ipilimumab | 224/426 (52.6%) | 272/426 (63.8%) | 421/426 (98.8%) |
| Placebo + Nivolumab + Ipilimumab | 217/423 (51.3%) | 257/423 (60.8%) | 416/423 (98.3%) |
| Event | Cabozantinib + Nivolumab + Ipilimumab | Placebo + Nivolumab + Ipilimumab |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 45/426 | 11/423 |
| Aspartate aminotransferase increasedInvestigations | 34/426 | 13/423 |
| Immune-mediated hepatitisHepatobiliary disorders | 20/426 | 3/423 |
| DiarrhoeaGastrointestinal disorders | 14/426 | 17/423 |
| COVID-19Infections and infestations | 16/426 | 17/423 |
| Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 13/426 | 15/423 |
| PneumoniaInfections and infestations | 13/426 | 10/423 |
| Adrenal insufficiencyEndocrine disorders | 11/426 | 12/423 |
| ColitisGastrointestinal disorders | 5/426 | 10/423 |
| VomitingGastrointestinal disorders | 2/426 | 9/423 |
| Event | Cabozantinib + Nivolumab + Ipilimumab | Placebo + Nivolumab + Ipilimumab |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 216/426 | 108/423 |
| Alanine aminotransferase increasedInvestigations | 204/426 | 89/423 |
| Aspartate aminotransferase increasedInvestigations | 195/426 | 74/423 |
| FatigueGeneral disorders | 133/426 | 129/423 |
| PruritusSkin and subcutaneous tissue disorders | 106/426 | 131/423 |
| HypertensionVascular disorders | 125/426 | 45/423 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 123/426 | 26/423 |
| HypothyroidismEndocrine disorders | 122/426 | 81/423 |
| Decreased appetiteMetabolism and nutrition disorders | 118/426 | 84/423 |
| NauseaGastrointestinal disorders | 112/426 | 105/423 |
The Intent-to-Treat (ITT) population was defined as all randomized participants regardless of whether any study treatment or the correct study treatment was received.
| Age, Categorical(Participants) | Cabozantinib + Nivolumab + Ipilimumab | Placebo + Nivolumab + Ipilimumab | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 277 | 276 | 553 |
| >=65 years | 151 | 151 | 302 |
| Sex: Female, Male(Participants) | Cabozantinib + Nivolumab + Ipilimumab | Placebo + Nivolumab + Ipilimumab | Total |
|---|---|---|---|
| Female | 102 | 115 | 217 |
| Male | 326 | 312 | 638 |
| Ethnicity (NIH/OMB)(Participants) | Cabozantinib + Nivolumab + Ipilimumab | Placebo + Nivolumab + Ipilimumab | Total |
|---|---|---|---|
| Hispanic or Latino | 130 | 127 | 257 |
| Not Hispanic or Latino | 263 | 273 | 536 |
| Unknown or Not Reported | 35 | 27 | 62 |
| Race (NIH/OMB)(Participants) | Cabozantinib + Nivolumab + Ipilimumab | Placebo + Nivolumab + Ipilimumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 10 | 14 |
| Asian | 29 | 33 | 62 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| Black or African American | 3 | 6 | 9 |
| White | 339 | 331 | 670 |
| More than one race | 2 | 2 | 4 |
| Unknown or Not Reported | 51 | 43 | 94 |
Showing the first 100 of 159 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2019 to primary completion in Jan 2022, 31 months.
Results were first posted in Sep 2025, 3 years 7 months after primary completion. A results delay was requested in Jan 2023.
Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's 31 months is below that.
Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabozantinib